Sunday, July 24, 2016

In conversation with Dr. Paul Lem

In conversation with Dr. Paul Lem

July 19, 2016 by · Leave a Comment 

Tweet As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides fast and inexpensive sample-to-result DNA testing. One-in-three people carry genetic mutations and carrying a CYP2C19 mutation can impair drug metabolism. Some […]

Academic centers, companies launch Mass. AZ R&D center

Academic centers, companies launch Mass. AZ R&D center

July 15, 2016 by · Leave a Comment 

Tweet The Massachusetts Life Sciences Center (MLSC), Massachusetts General Hospital (MGH) and five leading BioPharma companies have launched the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS) to find therapies for Alzheimer’s disease. The new center will be located at MGH.  Industry partners, including AbbVie, Biogen, Janssen Pharmaceuticals, Merck and Sunovion Pharmaceuticals, have committed $1.25-million in […]

Congress passes Comprehensive Addiction and Recovery Act

Congress passes Comprehensive Addiction and Recovery Act

July 14, 2016 by · Leave a Comment 

Tweet The United States Senate on Wednesday voted overwhelmingly to pass the Comprehensive Addiction and Recovery Act (CARA). The Senate vote follows a similar near-unanimous vote in the House of Representatives last week and will send the bill to the President for his signature. The American Society of Addiction Medicine (ASAM) welcomed passage of the […]

Braeburn provides update on training sessions for Probuphine

Braeburn provides update on training sessions for Probuphine

July 12, 2016 by · Leave a Comment 

Tweet Healthcare provider training and certification for Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant will take place on July 15-17 in Denver by Titan’s marketing partner, closely-held Braeburn Pharmaceuticals. The FDA cleared Probuphine in late May as the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses […]

Braeburn taking path as pill-free pharma company

Braeburn taking path as pill-free pharma company

July 12, 2016 by · Leave a Comment 

Tweet Closely-held Braeburn Pharmaceuticals, which in late May received FDA approval to market the first ever six-month implant of buprenorphine for opioid dependence, is developing a portfolio of long-acting implants and injectables that improve public health and social cost outcomes associated with drug diversion, misuse and non-compliance. “This is the way of the future,” Behshad […]

Buprenorphine patient limit raised to 275

Buprenorphine patient limit raised to 275

July 7, 2016 by · Leave a Comment 

Tweet The Obama Administration will raise to 275 from 100 the limit on the number of patients with opioid addiction that certain physicians can treat with buprenorphine. The move was part of several announced by the administration as part of an effort to stem the opioid abuse epidemic that is killing nearly 80 people from […]

FDA accepts Revive’s IND for Phase 2 bucillamine study

FDA accepts Revive’s IND for Phase 2 bucillamine study

July 6, 2016 by · Leave a Comment 

Tweet The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria. “This marks another significant milestone for Revive and we look forward to initiating this Phase 2 study shortly,” Fabio Chianelli, president, said in a statement. Cystinuria is a rare autosomal […]

Roth resumes coverage of CymaBay

Roth resumes coverage of CymaBay

July 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $4 price target. The stock closed at $1.57 on Friday. “In our opinion, while catalysts for the next 12-to-18 months are limited, the potential partnering of arhalofenate could be a significant driver for the shares, enhancing CymaBay’s coffers, validating […]

Rodman starts NeuroMetrix at buy

Rodman starts NeuroMetrix at buy

June 29, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device company aimed at management of chronic intractable pain due to conditions such as diabetes, fibromyalgia and arthritis. “In our view, the company’s […]

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Next Page »

Email Newsletters with Constant Contact
Google+